Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontamalimab maintenance in moderate to severe ulcerative colitis
NCT03290781Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 37
01
Overview
A Phase 3 trial of ontamalimab in ulcerative colitis (UC), sponsored by Takeda. Started Apr 2018; status: completed.
02
Drugs
ontamalimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03290781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290781.